Consensus on the treatment of allergic asthma with sublingual house dust mite immunotherapy in the field of pneumology. (3rd October 2021)

• Record Type: Journal Article
• Authors: Plaza, Vicente; Arnedillo, Aurelio; Blanco-Aparicio, Marina; Ignacio, José María; Urrutia, Isabel
• Is Part Of: Expert review of respiratory medicine. Volume 15:Number 10(2021)
• Page Start: 1245
• Page End: 1249
• Publication Date: 2021-10-03
• Subjects: Allergy -- asthma -- immunotherapy -- mites -- subcutaneous -- sublingual; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2021.1942846
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction : Many patients sensitized to mites remain symptomatic and uncontrolled despite traditional treatment. Sublingual immunotherapy (SLIT) has demonstrated to reduce the symptoms of allergic rhinitis, the need for additional drug treatments, and to reduce the number of moderate and severe exacerbations in patients with allergic asthma caused by mites that had not been adequately controlled. Areas covered : After reviewing the most recent literature, a scientific committee composed by five pneumologists experts in asthma proposed 41 items that addressed the diagnosis of allergic asthma caused by mites, the role of house dust mite (HDM) SLIT tablet in the therapeutic plan and in the control of the disease, and the profile of patients with asthma candidates for this therapy. Through a modified Delphi method, the items were send to 106 pneumologists involved in asthma to be agreed. Expert opinion : The high degree of consensus reached by the panel of pneumologists shows the importance of HDM SLIT tablet in the treatment of allergic asthma caused by mites, particularly taking into account that they barely use this therapy because until now they did not have a registered treatment with solid evidence of efficacy and safety.